IOLCP receives EDQM CEP Certificate for Clopidogrel Besilate
IOL Chemicals and Pharmaceuticals Limited announced on February 24, 2026, that it received a Certificate of Suitability (CEP) from EDQM for its API product, Clopidogrel Besilate, on February 23, 2026. This is in addition to an existing CEP for Clopidogrel Bisulphate. Clopidogrel is an antiplatelet medication.
Receiving a CEP from EDQM is a positive development that enhances the marketability and regulatory standing of the product in Europe, potentially leading to increased sales and market share. However, it's an addition to an existing certificate, not a completely new product launch, hence medium impact.
The company received a significant certification (CEP) from a regulatory body (EDQM) for one of its key API products, which is positive for its market access and credibility.
IOL Chemicals and Pharmaceuticals Limited (IOLCP) announced on 24th February 2026 that the European Directorate for the Quality of Medicines & Health Care (EDQM) has granted a Certificate of Suitability (CEP) for the company's API product, Clopidogrel Besilate. This certificate was issued on 23rd February 2026.
This new CEP is in addition to the existing valid CEP that IOLCP already holds for its product, Clopidogrel Bisulphate. Clopidogrel is an important antiplatelet medication primarily used in the treatment and prevention of cardiovascular diseases.
The company has informed both the National Stock Exchange of India Ltd. and BSE Limited about this development, in compliance with SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
What to do with a filing like this
IOL Chemicals and Pharmaceuticals Limited filed this with the NSE as a statutory disclosure, categorised under product launches. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by IOL Chemicals and Pharmaceuticals Limited. Read the original for the full detail.